Group A | Group B | p value | |
---|---|---|---|
Average VAS score at the first week | |||
Mean ± standard deviation | 3.9 ± 1 | 6.6 ± 0.7 | < 0.001 |
Median (minimum–maximum) | 4 (3–6) | 7 (6–8) | |
Fever days, n (%) | |||
< 5 days | 8 (38.1%) | 2 (11.1%) | 0.004 |
5–10 days | 12 (57.1%) | 7 (38.9%) | |
> 10 days | 1 (4.8%) | 9 (50%) | |
Fever days, median (interquartile range) | 5 (2) | 10 (5) | 0.003 |
Free-time-to-PES symptoms (days) | |||
Mean ± standard deviation | 7.2 ± 3.6 | 14.5 ± 4.5 | < 0.001 |
Median (minimum–maximum) | 6 (3–17) | 14 (5–21) | |
Ascites occurrence, number of patients (%) | 2 (13.3%) | 3 (23.1%) | 0.5 |
Frequency of ALT levels elevation | |||
At month 1 | 9 (60%) | 12 (92.3%) | 0.084 (FE) |
At month 3 | 7 (46.7%) | 8 (61.5%) | 0.431 |
Frequency of AST levels elevation | |||
At month 1 | 11 (73.3%) | 8 (61.5%) | 0.689 (FE) |
At month 3 | 11 (73.3%) | 10 (76.9%) | 1.000 (FE) |
Frequency of total bilirubin levels elevation | |||
At month 1 | 5 (33.3%) | 4 (30.8%) | 1.000 (FE) |
At month 3 | 7 (46.7%) | 6 (46.2%) | 0.978 |
Frequency of INR levels elevation | |||
At month 1 | 2 (13.3%) | 2 (15.4%) | 1.000 (FE) |
At month 3 | 3 (20%) | 2 (15.4%) | 1.000 (FE) |